The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...

India is home to the third-largest population of people living with HIV/AIDS, with women accounting for a significant portion ...

Move will require insurers to cover self-collected samples for HPV testing without cost-sh ...

“While the human penis functions primarily to transfer sperm, our result suggests its unusual large size evolved as a sexual ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept Therapeutics’ relacorilant has improved overall survival (OS) in a phase 3 ovarian cancer study, building on interim data published last year and giving the biotech momentum as it heads into ...

Read our HBADA X7 review. Discover the world’s first AI lumbar support and health massage chair designed for 10+ hour workdays.

Avacta Group reported strong operational progress during 2025 on Tuesday as the clinical-stage biopharmaceutical company ...

As India prepares for Union Budget 2026–27, healthcare experts are urging policymakers to pivot spending toward prevention, early diagnosis, digital safeguards and nutrition-led interventions.

The boss of Wetherby-based biopharmaceutical company Avacta says she is “incredibly excited” about the company’s prospects ...

Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform ...

Corcept Therapeutics, sponsor of the ROSELLA trial, is currently evaluating relacorilant in other solid tumors, including platinum-sensitive ovarian cancer, endometrial cancer, cervical cancer, ...